AtriCure (ATRC) vs Bausch + Lomb (BLCO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AtriCure (ATRC) has outperformed Bausch + Lomb (BLCO) over the past year, gaining 56.2% versus a gain of 18.3%. Bausch + Lomb is the larger company by market cap ($6.19 billion vs $2.71 billion), about 2.3 times the size, while AtriCure is growing revenue faster (+14.9% vs +6.5%). On valuation, Bausch + Lomb trades at a lower forward P/E (15.6x vs 122.8x for AtriCure).
AtriCure converts more of its revenue into profit, with a net margin of -2.1% versus -7.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | BLCO |
|---|---|---|
| Share price | $53.31 | $17.34 |
| Market cap | $2.71B | $6.19B |
| 1-day change | -0.69% | +0.93% |
| YTD return | +34.76% | +1.52% |
| 1-year return | +56.24% | +18.28% |
| 5-year return | -25.30% | — |
| P/E ratio (TTM) | 253.86 | — |
| Forward P/E | 122.84 | 15.57 |
| EPS (TTM) | $0.21 | $-0.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | $5.10B |
| Revenue growth (YoY) | +14.88% | +6.47% |
| Net income (latest FY) | $-11.45M | $-360.00M |
| Gross margin | 74.98% | — |
| Operating margin | -1.77% | 2.22% |
| Net margin | -2.14% | -7.06% |
| 52-week high | $61.70 | $18.92 |
| 52-week low | $25.36 | $13.77 |
| Distance from 52-week high | -13.60% | -8.33% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +2.96% | +11.82% |
| Average volume | 1.10M | 392.81K |
| Shares outstanding | 50.87M | 357.17M |
| Employees | 1,350 | 13,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bausch + Lomb is about 2.3 times larger than AtriCure by market value ($6.19B vs $2.71B).
- ATRC has outperformed BLCO by 38.0 percentage points over the past year.
- AtriCure grew revenue faster in its latest fiscal year (+14.88% vs +6.47%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About Bausch + Lomb
BLCO stock →Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Health Care · Ophthalmic Goods · 13,000 employees
ATRC vs BLCO FAQ
Which is bigger, AtriCure or Bausch + Lomb?
Bausch + Lomb (BLCO) is larger, with a market capitalization of $6.19B compared with $2.71B for AtriCure (ATRC).
Which stock has performed better over the past year, ATRC or BLCO?
ATRC returned +56.24% over the past 12 months, compared with +18.28% for BLCO (price return, excluding dividends). Past performance does not predict future results.
Are AtriCure and Bausch + Lomb in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for AtriCure and Ophthalmic Goods for Bausch + Lomb.